CD40 (P25942) variants and mutations
CD40 (also known as P25942) is a human protein-coding gene encoding a tumor necrosis factor receptor superfamily member 5 protein. Its engagement on B cells and antigen-presenting cells promotes antibody class switching, germinal-center responses, and broader adaptive immune activation. Loss-of-function variants can cause hyper-IgM immunodeficiency, while excessive signaling contributes to autoimmunity and inflammation. This analysis covers 429 CD40 variants and mutations. Of these, 93% have computational variant effect predictions. Disease context includes hyper-IgM syndrome type 3, rheumatoid arthritis, and Graves disease. Example CD40 variants include M1?, R3C, and R3G.
Variant analysis overview
- Gene: CD40
- Protein: P25942
- UniProt accession: P25942
- Organism: Homo sapiens
- Variants analyzed: 429
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 282 unspecified-consequence records; 67 missense variants; 71 synonymous variants; 3 splice-region variants; 2 frameshift variants; 2 stop-gained variants; 1 in-frame insertions; 1 substitution
- Prediction scores: 401 variants have prediction scores (93% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: hyper-IgM syndrome type 3, rheumatoid arthritis, Graves disease, inflammatory bowel disease, Crohn disease, multiple sclerosis, bipolar disorder, Kawasaki disease, thyrotoxicosis, mathematical ability, non-Hodgkin lymphoma, ACPA-positive rheumatoid arthritis.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 2 post-translational modification sites.
- Structural context: 26 variants have structural context.
- PTM context: 6 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable CD40 variants
Examples include M1?, R3C, R3G, R3H, R3L, R3P, R3S, R3R. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1?, NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- R3C (p.Arg3Cys), NCI-TCGA TCGA novel, TOPMed rs1600650328, REVEL 0.25, CADD 22.20, Variant assessed as somatic; moderate impact.
- R3G (p.Arg3Gly), TOPMed rs1600650328, MetaLR 0.44, MetaSVM -0.64
- R3H (p.Arg3His), rs1309660087, NCI-TCGA Cosmic COSV6484, cosmic curated COSV64848, TOPMed rs1309660087, REVEL 0.25, CADD 21.20, Variant assessed as somatic; moderate impact.
- R3L (p.Arg3Leu), TOPMed rs1309660087, gnomAD rs1309660087, REVEL 0.14, CADD 15.70
- R3P (p.Arg3Pro), TOPMed rs1309660087, gnomAD rs1309660087, REVEL 0.17, CADD 17.20
- R3S (p.Arg3Ser), gnomAD 20-46118350-C-A, REVEL 0.10, CADD 22.10
- R3R (p.Arg3Arg), rs1336243656, gnomAD 20-46118352-T-C, CADD 5.11
- L4R (p.Leu4Arg), ExAC rs746583774, gnomAD rs746583774, REVEL 0.60, CADD 22.50
- L4L (p.Leu4Leu), rs1469935635, gnomAD 20-46118353-C-T, CADD 6.46
- P5H (p.Pro5His), NCI-TCGA Cosmic COSV6484, cosmic curated COSV64848, Variant assessed as somatic; moderate impact.
- P5T (p.Pro5Thr), NCI-TCGA TCGA novel, MetaLR 0.52, MetaSVM -0.50, Variant assessed as somatic; moderate impact.
- L6L (p.Leu6Leu), rs1281907367, gnomAD 20-46118359-C-T, CADD 6.30
- L6P (p.Leu6Pro), gnomAD 20-46118360-T-C, REVEL 0.53, CADD 23.60
- Q7* (p.Gln7Ter), gnomAD rs1357930196
- Q7H (p.Gln7His), Ensembl rs2085252096, MetaLR 0.46, MetaSVM -0.53
- Q7P (p.Gln7Pro), ExAC rs768187312, gnomAD rs768187312, REVEL 0.48, CADD 14.10
- C8G (p.Cys8Gly), rs113207193, ClinGen CA9888331, ClinVar RCV001911699, 1000Genomes rs113207193, REVEL 0.47, CADD 25.30, Uncertain significance, not provided
- C8C (p.Cys8Cys), rs1481881300, gnomAD 20-46118367-C-T, CADD 13.40
- V9F (p.Val9Phe), TOPMed rs910523454, gnomAD rs910523454, REVEL 0.51, CADD 22.80
- V9I (p.Val9Ile), cosmic curated COSV10970, TOPMed rs910523454, gnomAD rs910523454, REVEL 0.16, CADD 15.30
- L10I (p.Leu10Ile), ExAC rs748416131, TOPMed rs748416131, gnomAD rs748416131, REVEL 0.26, CADD 18.50
- L10F (p.Leu10Phe), gnomAD 20-46118371-C-T, REVEL 0.14, CADD 15.00
- W11* (p.Trp11Ter), rs1211645093, ClinGen CA409200600, ClinVar RCV002876679, TOPMed rs1211645093, CADD 40.00, Pathogenic
- W11S (p.Trp11Ser), gnomAD 20-46118375-G-C, REVEL 0.64, CADD 31.00
- G12S (p.Gly12Ser), gnomAD 20-46118377-G-A, REVEL 0.42, CADD 31.00
- G12D (p.Gly12Asp), gnomAD 20-46118378-G-A, REVEL 0.57, CADD 29.90
- C13R (p.Cys13Arg), gnomAD 20-46118380-T-C, REVEL 0.62, CADD 27.50
- C13G (p.Cys13Gly), gnomAD 20-46118380-T-G, REVEL 0.39, CADD 24.90
- L15L (p.Leu15Leu), gnomAD 20-46118386-C-T, CADD 11.40
- T16P (p.Thr16Pro), gnomAD 20-46118389-A-C, REVEL 0.46, CADD 24.30
- T16I (p.Thr16Ile), gnomAD 20-46118390-C-T, REVEL 0.38, CADD 24.70
- T16T (p.Thr16Thr), rs1008453074, gnomAD 20-46118391-C-T, CADD 10.60
- A17S (p.Ala17Ser), rs770177808, ClinGen CA9888333, ClinVar RCV002725847, ExAC rs770177808, REVEL 0.18, CADD 4.67, Uncertain significance, not provided
- A17T (p.Ala17Thr), rs770177808, NCI-TCGA Cosmic COSV6484, cosmic curated COSV64848, ExAC rs770177808, REVEL 0.19, CADD 5.45, Uncertain significance
- A17V (p.Ala17Val), gnomAD 20-46118393-C-T, REVEL 0.23, CADD 23.90
- V18D (p.Val18Asp), gnomAD rs2085324142, REVEL 0.64, CADD 29.00
- V18I (p.Val18Ile), TOPMed rs1440428121, gnomAD rs1440428121, REVEL 0.25, CADD 25.50
- V18V (p.Val18Val), rs771363187, gnomAD 20-46121822-C-A, CADD 14.10
- H19Q (p.His19Gln), rs1204102934, ClinGen CA409202648, ClinVar RCV001700681, TOPMed rs1204102934, AlphaMissense 0.12, MetaLR 0.35, Likely benign, not provided
- H19R (p.His19Arg), ExAC rs774936391, gnomAD rs774936391, REVEL 0.15, CADD 18.50
- H19H (p.His19His), rs1204102934, gnomAD 20-46121825-T-C, AlphaMissense 0.12, MetaLR 0.35
- P20T (p.Pro20Thr), gnomAD 20-46121826-C-A, REVEL 0.26, CADD 14.30
- P20L (p.Pro20Leu), gnomAD 20-46121827-C-T, REVEL 0.17, CADD 16.10
- P20Q (p.Pro20Gln), gnomAD 20-46121827-C-A, REVEL 0.20, CADD 22.40
- P20P (p.Pro20Pro), rs2085324517, gnomAD 20-46121828-A-G, CADD 8.79
- P22L (p.Pro22Leu), ExAC rs759483970, gnomAD rs759483970, REVEL 0.22, CADD 16.80
- P22P (p.Pro22Pro), gnomAD 20-46121834-A-G, CADD 9.71
- P23A (p.Pro23Ala), NCI-TCGA Cosmic COSV1009, cosmic curated COSV10095, Variant assessed as somatic; moderate impact.
- P23H (p.Pro23His), Ensembl rs2085324676, MetaLR 0.44, MetaSVM -0.66
- T24S (p.Thr24Ser), NCI-TCGA TCGA novel, REVEL 0.13, CADD 11.40, Variant assessed as somatic; moderate impact.
- T24I (p.Thr24Ile), gnomAD 20-46121839-C-T, REVEL 0.18, CADD 14.80
- A25S (p.Ala25Ser), rs147677886, ClinGen CA9888358, ClinVar RCV002031307, ClinVar RCV002549047, REVEL 0.10, CADD 5.57, Uncertain significance, Inborn genetic diseases; not provided
- A25A (p.Ala25Ala), rs775472655, gnomAD 20-46121843-A-G, CADD 8.42
- C26Q (p.Cys26Gln), UniProt VAR 039301, MetaLR 1.00, MetaSVM 0.86, Uncertain significance, in bladder carcinoma cell line Hu549
- C26G (p.Cys26Gly), gnomAD 20-46121844-T-G, REVEL 0.83, CADD 28.40
- R27S (p.Arg27Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E28D (p.Glu28Asp), gnomAD 20-46121852-A-C, REVEL 0.18, CADD 10.00
- E28E (p.Glu28Glu), rs760957101, gnomAD 20-46121852-A-G, CADD 9.49
- K29R (p.Lys29Arg), gnomAD 20-46121854-A-G, REVEL 0.26, CADD 22.60
- K29K (p.Lys29Lys), gnomAD 20-46121855-A-G, CADD 2.68
- Q30H (p.Gln30His), TOPMed rs2085325012
- Q30L (p.Gln30Leu), NCI-TCGA Cosmic COSV1009, cosmic curated COSV10095, Variant assessed as somatic; moderate impact.
- Q30R (p.Gln30Arg), rs2145590363, ClinGen CA409202933, ClinVar RCV001958268, Ensembl rs2145590363, AlphaMissense 0.19, MetaLR 0.80, Uncertain significance, not provided
- Q30E (p.Gln30Glu), gnomAD 20-46121856-C-G, REVEL 0.30, CADD 22.90
- Y31H (p.Tyr31His), Ensembl rs2145590386, MetaLR 0.93, MetaSVM 0.65
- L32P (p.Leu32Pro), ExAC rs764464873, gnomAD rs764464873, REVEL 0.45, CADD 9.58
- L32V (p.Leu32Val), Ensembl rs2145590403, MetaLR 0.61, MetaSVM -0.50
- L32L (p.Leu32Leu), gnomAD 20-46121862-C-T, CADD 12.20
- I33T (p.Ile33Thr), TOPMed rs1404215817, gnomAD rs1404215817, REVEL 0.28, CADD 1.25
- N34S (p.Asn34Ser), rs2145590458, ClinGen CA409203001, ClinVar RCV002045213, Ensembl rs2145590458, AlphaMissense 0.09, MetaLR 0.55, Uncertain significance, not provided
- N34N (p.Asn34Asn), rs2085325306, gnomAD 20-46121870-C-T, CADD 12.00
- S35C (p.Ser35Cys), ExAC rs750234130, gnomAD rs750234130, REVEL 0.30, CADD 21.10
- S35G (p.Ser35Gly), rs750234130, UniProt VAR 039302, ExAC rs750234130, gnomAD rs750234130, REVEL 0.12, CADD 9.16, Uncertain significance, in bladder carcinoma cell line Hu549
- S35N (p.Ser35Asn), ExAC rs762843067, gnomAD rs762843067, REVEL 0.07, CADD 8.20
- S35T (p.Ser35Thr), gnomAD 20-46121872-G-C, REVEL 0.06, MetaLR 0.25
- S35S (p.Ser35Ser), gnomAD 20-46121873-T-C, CADD 5.75
- C37G (p.Cys37Gly), UniProt VAR 077569, MetaLR 1.00, MetaSVM 0.86, Pathogenic, in HIGM3
- C37W (p.Cys37Trp), gnomAD 20-46121879-C-G, REVEL 0.85, MetaLR 1.00
- C38F (p.Cys38Phe), NCI-TCGA TCGA novel, MetaLR 1.00, MetaSVM 0.83, Variant assessed as somatic; moderate impact.
- C38R (p.Cys38Arg), gnomAD 20-46121880-T-C, REVEL 0.93, MetaLR 1.00
- S39F (p.Ser39Phe), rs2515707168, ClinGen CA409203106, ClinVar RCV002777572, Uncertain significance, Inborn genetic diseases
- S39P (p.Ser39Pro), ExAC rs766167612, TOPMed rs766167612, gnomAD rs766167612, REVEL 0.42, CADD 14.00
- S39T (p.Ser39Thr), UniProt VAR 039303, Uncertain significance, in bladder carcinoma cell line Hu549
- L40L (p.Leu40Leu), rs1350784951, gnomAD 20-46121886-T-C, CADD 5.06
- C41C (p.Cys41Cys), rs751549823, gnomAD 20-46121891-C-T, CADD 12.00
- Q42E (p.Gln42Glu), gnomAD 20-46121892-C-G, REVEL 0.12, MetaLR 0.16
- Q42H (p.Gln42His), gnomAD 20-46121894-G-T, REVEL 0.31, MetaLR 0.28
- P43P (p.Pro43Pro), rs2085325980, gnomAD 20-46121897-A-G, CADD 22.70
- G44V (p.Gly44Val), NCI-TCGA Cosmic COSV6484, cosmic curated COSV64847, Variant assessed as somatic; moderate impact.
- G44G (p.Gly44Gly), rs1323500867, gnomAD 20-46122234-A-G, CADD 15.30
- Q45Q (p.Gln45Gln), gnomAD 20-46122237-G-A, CADD 8.52
- K46E (p.Lys46Glu), gnomAD 20-46122238-A-G, REVEL 0.45, MetaLR 0.77
- L47L (p.Leu47Leu), gnomAD 20-46122243-G-A, CADD 10.20, SIFT 0.00
- V48L (p.Val48Leu), gnomAD 20-46122244-G-T, REVEL 0.25, MetaLR 0.64
- S49N (p.Ser49Asn), rs1299633835, ClinGen CA409203370, ClinVar RCV002013670, gnomAD rs1299633835, REVEL 0.19, CADD 0.74, Uncertain significance, not provided
- S49S (p.Ser49Ser), rs541686651, gnomAD 20-46122249-T-C, CADD 1.17
- D50G (p.Asp50Gly), rs1568905843, gnomAD 20-46122249-T-TG, CADD 25.30
- D50D (p.Asp50Asp), gnomAD 20-46122252-C-T, CADD 10.30
- C51S (p.Cys51Ser), Ensembl rs2085332974, MetaLR 1.00, MetaSVM 0.85
- T52K (p.Thr52Lys), gnomAD 20-46122257-C-A, REVEL 0.30, MetaLR 0.72
- T52T (p.Thr52Thr), rs767422189, gnomAD 20-46122258-A-G, CADD 0.85
- E53* (p.Glu53Ter), rs2515708304, ClinGen CA409203443, ClinVar RCV002848000, CADD 34.00, Pathogenic
- E53G (p.Glu53Gly), TOPMed rs1283983293, MetaLR 0.52, MetaSVM -0.57
- F54V (p.Phe54Val), gnomAD 20-46122262-T-G, REVEL 0.29, MetaLR 0.28
- T55T (p.Thr55Thr), rs752136889, gnomAD 20-46122267-T-C, CADD 0.58
- E56K (p.Glu56Lys), Ensembl rs866558753, MetaLR 0.37, MetaSVM -0.46
- E56E (p.Glu56Glu), gnomAD 20-46122270-A-G, CADD 0.17
- T57M (p.Thr57Met), rs2515708347, ClinGen CA409203536, ClinVar RCV003050557, ClinVar RCV004765644, REVEL 0.64, CADD 23.50, Conflicting interpretations, not provided; Hyper-IgM syndrome type 3
- T57R (p.Thr57Arg), gnomAD 20-46122272-C-G, REVEL 0.59, MetaLR 0.91
- T57T (p.Thr57Thr), rs115724543, gnomAD 20-46122273-G-A, CADD 0.64
- E58Q (p.Glu58Gln), gnomAD 20-46122274-G-C, REVEL 0.07, MetaLR 0.46
- E58* (p.Glu58Ter), gnomAD 20-46122274-G-T, CADD 28.60
- E58E (p.Glu58Glu), gnomAD 20-46122276-A-G, CADD 2.07
- C59Y (p.Cys59Tyr), gnomAD rs2085333473, MetaLR 1.00, MetaSVM 1.09
- L60V (p.Leu60Val), gnomAD 20-46122280-C-G, REVEL 0.12, MetaLR 0.13
- L60F (p.Leu60Phe), gnomAD 20-46122280-C-T, REVEL 0.16, MetaLR 0.19
- C62* (p.Cys62Ter), gnomAD 20-46122288-C-A, CADD 24.90
- C62C (p.Cys62Cys), rs753518969, gnomAD 20-46122288-C-T, CADD 3.62
- G63D (p.Gly63Asp), rs1261429888, ClinGen CA409203646, ClinVar RCV000780087, TOPMed rs1261429888, REVEL 0.14, CADD 0.22, Uncertain significance, not specified
- G63R (p.Gly63Arg), rs756898850, ClinGen CA409203643, ClinVar RCV003009895, REVEL 0.18, CADD 0.01, Uncertain significance, not provided
- G63S (p.Gly63Ser), rs756898850, ClinGen CA9888391, NCI-TCGA Cosmic COSV1009, cosmic curated COSV10095, REVEL 0.13, CADD 0.00, Uncertain significance, not provided
- G63V (p.Gly63Val), TOPMed rs1261429888, gnomAD rs1261429888, REVEL 0.23, CADD 1.14, Uncertain significance
- S65R (p.Ser65Arg), 1000Genomes rs202208745, ExAC rs202208745, gnomAD rs202208745, REVEL 0.25, CADD 16.80, Likely benign
- S65S (p.Ser65Ser), rs202208745, gnomAD 20-46122297-C-T, CADD 6.58
- E66K (p.Glu66Lys), NCI-TCGA TCGA novel, REVEL 0.46, CADD 24.70, Variant assessed as somatic; moderate impact.
- E66Q (p.Glu66Gln), gnomAD rs1208355184, REVEL 0.30, CADD 23.70
- F67Y (p.Phe67Tyr), TOPMed rs1442590284, gnomAD rs1442590284, REVEL 0.29, CADD 22.10
- F67F (p.Phe67Phe), rs746276099, gnomAD 20-46122303-C-T, CADD 8.10
- L68V (p.Leu68Val), Ensembl rs2085334054, MetaLR 0.23, MetaSVM -0.81
- L68L (p.Leu68Leu), rs142258778, gnomAD 20-46122306-A-G, CADD 3.57
- D69E (p.Asp69Glu), ESP rs371950759, ExAC rs371950759, TOPMed rs371950759, gnomAD rs371950759, REVEL 0.04, CADD 7.27
- D69H (p.Asp69His), Ensembl rs2085334202, REVEL 0.19, CADD 9.10
- D69Y (p.Asp69Tyr), Ensembl rs2085334202, REVEL 0.31, CADD 15.70
- D69G (p.Asp69Gly), gnomAD 20-46122308-A-G, REVEL 0.25, MetaLR 0.24
- T70A (p.Thr70Ala), rs2145592034, ClinGen CA409203747, ClinVar RCV001969866, Ensembl rs2145592034, REVEL 0.06, CADD 7.28, Uncertain significance, not provided
- T70I (p.Thr70Ile), cosmic curated COSV10592, ExAC rs747024806, TOPMed rs747024806, gnomAD rs747024806, REVEL 0.10, CADD 15.80, Uncertain significance
- T70N (p.Thr70Asn), ExAC rs747024806, TOPMed rs747024806, gnomAD rs747024806, REVEL 0.10, CADD 14.50, Uncertain significance, Inborn genetic diseases
- N72H (p.Asn72His), gnomAD 20-46122316-A-C, REVEL 0.32, MetaLR 0.45
- R73T (p.Arg73Thr), Ensembl rs2085334473
- R73R (p.Arg73Arg), gnomAD 20-46122321-A-G, CADD 5.96
- T75A (p.Thr75Ala), NCI-TCGA Cosmic COSV1009, cosmic curated COSV10095, MetaLR 0.20, MetaSVM -0.99, Variant assessed as somatic; moderate impact.
- p.Thr75 His76insGlnArg, gnomAD 20-46122326-C-CAC, CADD 1.49
- T75T (p.Thr75Thr), gnomAD 20-46122327-A-G, CADD 1.26
- H76N (p.His76Asn), gnomAD rs1473553396, REVEL 0.03, CADD 16.80
- H76Q (p.His76Gln), TOPMed rs2085334610, MetaLR 0.18, MetaSVM -1.01
- H76H (p.His76His), gnomAD 20-46122330-C-T, CADD 4.99
- C77F (p.Cys77Phe), Ensembl rs17855908, MetaLR 0.76, MetaSVM 0.72
- C77C (p.Cys77Cys), rs768876770, gnomAD 20-46122333-C-T, CADD 5.68
- H78Q (p.His78Gln), Ensembl rs17177493, REVEL 0.11, CADD 18.70
- Q79K (p.Gln79Lys), cosmic curated COSV10095, gnomAD rs1413770839, REVEL 0.25, CADD 14.90
- Q79R (p.Gln79Arg), Ensembl rs1568906027, REVEL 0.04, CADD 15.40
- Q79P (p.Gln79Pro), gnomAD 20-46122338-A-C, REVEL 0.25, MetaLR 0.13
- Q79Q (p.Gln79Gln), rs1367438937, gnomAD 20-46122339-G-A, CADD 8.15
- Q79H (p.Gln79His), gnomAD 20-46122339-G-C, REVEL 0.29, MetaLR 0.45
- H80Q (p.His80Gln), TOPMed rs2085335191, REVEL 0.54, CADD 22.90, Likely benign
- H80R (p.His80Arg), ESP rs376829285, TOPMed rs376829285, gnomAD rs376829285, REVEL 0.52, CADD 23.30
- K81K (p.Lys81Lys), gnomAD 20-46122345-A-G, CADD 9.50
- C83R (p.Cys83Arg), rs28931586, ClinGen CA127369, ClinVar RCV000019325, UniProt VAR 013628, AlphaMissense 0.96, MetaLR 0.90, Pathogenic, Hyper-IgM syndrome type 3
- C83Y (p.Cys83Tyr), TOPMed rs1177950070, MetaLR 0.89, MetaSVM 0.92
- C83C (p.Cys83Cys), rs776893342, gnomAD 20-46122351-C-T, CADD 7.11
- D84E (p.Asp84Glu), ExAC rs748382649, TOPMed rs748382649, gnomAD rs748382649, MetaLR 0.32, MetaSVM -0.80, Likely benign
- D84N (p.Asp84Asn), rs1406703700, TOPMed rs1406703700, REVEL 0.25, CADD 22.90, Variant assessed as somatic; moderate impact.
- D84D (p.Asp84Asp), rs748382649, gnomAD 20-46122354-C-T, CADD 8.48
- P85L (p.Pro85Leu), rs2515708647, ClinGen CA409204079, ClinVar RCV003026071, Uncertain significance, not provided
- P85T (p.Pro85Thr), ExAC rs769971386, gnomAD rs769971386, REVEL 0.30, CADD 21.20
- P85R (p.Pro85Arg), gnomAD 20-46122356-C-G, REVEL 0.39, MetaLR 0.46
- N86Y (p.Asn86Tyr), gnomAD 20-46122358-A-T, REVEL 0.50, MetaLR 0.64
- L87V (p.Leu87Val), rs768637864, ClinGen CA9888426, ClinVar RCV002636043, ExAC rs768637864, REVEL 0.21, CADD 11.20, Uncertain significance, not provided
- G88R (p.Gly88Arg), gnomAD 20-46122615-G-C, REVEL 0.34, MetaLR 0.68
- G88G (p.Gly88Gly), gnomAD 20-46122617-G-A, CADD 7.19
- R90Q (p.Arg90Gln), rs761229326, ClinGen CA9888428, cosmic curated COSV64848, ClinVar RCV001934182, REVEL 0.15, CADD 0.01, Uncertain significance, not provided
- R90W (p.Arg90Trp), rs144542285, ClinGen CA9888427, cosmic curated COSV64847, ClinVar RCV002658634, REVEL 0.32, CADD 17.40, Uncertain significance, not provided
- R90G (p.Arg90Gly), gnomAD 20-46122621-C-G, REVEL 0.43, MetaLR 0.43
- V91A (p.Val91Ala), rs750063104, ClinGen CA9888430, ClinVar RCV002859297, ExAC rs750063104, REVEL 0.28, CADD 21.20, Uncertain significance, Inborn genetic diseases
- V91F (p.Val91Phe), 1000Genomes rs764882779, ExAC rs764882779, TOPMed rs764882779, gnomAD rs764882779, MetaLR 0.64, MetaSVM -0.47
- V91I (p.Val91Ile), cosmic curated COSV64847, 1000Genomes rs764882779, ExAC rs764882779, TOPMed rs764882779, REVEL 0.11, CADD 11.80, Uncertain significance, Inborn genetic diseases
- V91V (p.Val91Val), gnomAD 20-46122626-C-T, CADD 3.93
- Q92R (p.Gln92Arg), gnomAD 20-46122628-A-G, REVEL 0.12, MetaLR 0.26
- Q93L (p.Gln93Leu), gnomAD 20-46122631-A-T, REVEL 0.21, MetaLR 0.33
Public CD40 analysis runs
- CD40 analysis run — CD40 (429 variants) — completed 2026-08-19